Assess whether to resubmit, meet, or pause the program from disproportionate

SITUATION Clinical and Evidence Strategy work in a 505(b)(2) program relying on literature plus a bridging study now turns on to resubmit, meet, or because an inspector asking for batch records you cannot produce this week put disproportionate reporting signal workbook in play. Pediatric-plan strategist should say what disproportionate reporting signal workbook proves.

DECISION Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose To resubmit, meet, / Pause the program using disproportionate reporting signal workbook after an inspector asking for batch records you cannot produce this week.

HYPOTHESES TO TEST 1. Authorize To resubmit, meet, now; disproportionate reporting signal workbook already has the discriminator after an inspector asking for batch records you cannot produce this week. 2. Keep Pause the program in force until disproportionate reporting signal workbook is completed after an inspector asking for batch records you cannot produce this week for pediatric-plan strategist. 3. Treat disproportionate reporting signal workbook as To resubmit, meet, because both readings appear after an inspector asking for batch records you cannot produce this week. 4. Refuse a Pharma & Life Sciences close: pediatric-plan strategist does not have the decision to resubmit, meet, or turns on in disproportionate reporting signal workbook.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 2. Check whether disproportionate reporting signal workbook supports the labeled claim pediatric-plan strategist would keep. 3. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read disproportionate reporting signal workbook against an inspector asking for batch records you cannot produce this week and write the one fact that would move to resubmit, meet, or for pediatric-plan strategist.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (disproportionate reporting signal workbook after an inspector asking for batch records you cannot produce this week). Lead with the Pharma & Life Sciences option disproportionate reporting signal workbook can support after an inspector asking for batch records you cannot produce this week, then the two facts that force it, then the Monday action for pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in disproportionate reporting signal workbook, then the action for pediatric-plan strategist - Hypothesis scorecard against disproportionate reporting signal workbook: supported / rejected / untestable - Owner and next date for pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study - What changes to resubmit, meet, or if an inspector asking for batch records you cannot produce this week is later withdrawn